Anxiolytic effects of Julibroside C1 isolated from Albizzia julibrissin in mice

Progress in Neuro-Psychopharmacology and Biological Psychiatry

Volumn 44, Issue , 2013, Pages 184-192

  Jung, Yang Hee ^a   Ha, Ri Ra ^a   Kwon, Seung Hwan ^a   Hong, Sa Ik ^a   Lee, Kun Ho ^b   Kim, Sun Yeou ^c   Lee, Seok Yong ^a   Jang, Choon Gon ^a  

^a Sungkyunkwan University   (South Korea)

^b Kyung Hee University   (South Korea)

^c Gachon University   (South Korea)

Author keywords

5 HT1A; Anxiolytic effects; Benzodiazepine; GABAA; Julibroside C1

Indexed keywords

2 DIPROPYLAMINO 8 HYDROXYTETRALIN; 7 AMINOFLUNITRAZEPAM; ANXIOLYTIC AGENT; BICUCULLINE; BRAIN RECEPTOR; FLUMAZENIL; FLUNITRAZEPAM; JULIBROSIDE C1; MUSCIMOL; N [2 [4 (2 METHOXYPHENYL) 1 PIPERAZINYL]ETHYL] N (2 PYRIDYL)CYCLOHEXANECARBOXAMIDE; UNCLASSIFIED DRUG;

ALBIZIA; ALBIZZIA JULIBRISSIN; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; AUTORADIOGRAPHY; BINDING KINETICS; CINGULATE GYRUS; CONTROLLED STUDY; DOSE RESPONSE; DRUG DOSE COMPARISON; DRUG EFFECT; DRUG POTENCY; DRUG STRUCTURE; HIPPOCAMPAL CA1 REGION; LOCOMOTION; MALE; MAZE TEST; MOTOR CORTEX; MOUSE; NONHUMAN; TRANQUILIZING ACTIVITY;

8-HYDROXY-2-(DI-N-PROPYLAMINO)TETRALIN; ALBIZZIA; ANALYSIS OF VARIANCE; ANIMALS; ANTI-ANXIETY AGENTS; AUTORADIOGRAPHY; BRAIN; DOSE-RESPONSE RELATIONSHIP, DRUG; FLUNITRAZEPAM; MALE; MAZE LEARNING; MICE; MICE, INBRED ICR; MOTOR ACTIVITY; MUSCIMOL; PLANT PREPARATIONS; PROTEIN BINDING; SAPONINS; TRITERPENES; TRITIUM;

EID: 84876014473     PISSN: 02785846     EISSN: 18784216     Source Type: Journal    
DOI: 10.1016/j.pnpbp.2013.02.012     Document Type: Article

References (56)

1. Ase A.R., Amdiss F., Hebert C., Huang N., Van Gelder N.M., Reader T.A. Effects of antipsychotic drugs on dopamine and serotonin contents and metabolites, dopamine and serotonin transporters, and serotonin(1A) receptors. J Neural Transm 1999, 106:75-105.
2. Barnard E.A., Darlison M.G., Fujita N., Glencorse T.A., Levitan E.S., Reale V., et al. Molecular biology of the GABAA receptor. Adv Exp Med Biol 1988, 236:31-45.
3. Belzung C. The genetic basis of the pharmacological effects of anxiolytics: a review based on rodent models. Behav Pharmacol 2001, 12:451-460.
4. Blier P., Lista A., De Montigny C. Differential properties of pre- and postsynaptic 5-hydroxytryptamine(1A) receptors in the dorsal raphe and hippocampus: I. Effect of spiperone. J Pharmacol Exp Ther 1993, 265:7-15.
5. Bonetti E.P., Pieri L., Cumin R. Benzodiazepine antagonist Ro 15-1788: neurological and behavioral effects. Psychopharmacology 1982, 78:8-18.
6. Bremner J.D., Innis R.B., White T., Fujita M., Silbersweig D., Goddard A.W., et al. SPECT [I-123]iomazenil measurement of the benzodiazepine receptor in panic disorder. Biol Psychiatry 2000, 47:96-106.
7. 3H]flunitrazepam binding throughout the rat brain: an autoradiographic study. J Pharmacol Exp Ther 1992, 263:1401-1414.
8. Chen S.P., Zhang R.Y., Ma L.B., Tu G.Z. Structure determination of three saponins from the stem bark of Albizzia julibrissin Durazz. Yaoxue Xuebao 1997, 32:110-115.
9. Clenet F., Hascoet M., Fillion G., Galons H., Bourin M. Role of GABA-ergic and serotonergic systems in the anxiolytic-like mechanism of action of a 5-HT-moduline antagonist in the mouse elevated plus maze. Behav Brain Res 2005, 158:339-348.
10. Dalvi A., Rodgers R.J. GABAergic influences on plus-maze behaviour in mice. Psychopharmacology 1996, 128:380-397.
11. DeVane C.L., Chiao E., Franklin M., Kruep E.J. Anxiety disorders in the 21st century: status, challenges, opportunities, and comorbidity with depression. Am J Manag Care 2005, 11:S344-S353.
12. Feighner J.P., Boyer W.F. Serotonin-1A anxiolytics: an overview. Psychopathology 1989, 22:21-26.
13. Heisler L.K., Chu H.M., Brennan T.J., Danao J.A., Bajwa P., Parsons L.H., et al. Elevated anxiety and antidepressant-like responses in serotonin 5-HT1A receptor mutant mice. Proc Natl Acad Sci U S A 1998, 95:15049-15054.
14. Herrera-Ruiz M., Gonzalez-Carranza A., Zamilpa A., Jimenez-Ferrer E., Huerta-Reyes M., Navarro-Garcia V.M. The standardized extract of Loeselia mexicana possesses anxiolytic activity through the γ-amino butyric acid mechanism. J Ethnopharmacol 2011, 138:261-267.
15. Hong S.I., Kwon S.H., Kim M.J., Ma S.X., Kwon J.W., Choi S.M., et al. Anxiolytic-like effects of Chrysanthemum indicum aqueous extract in mice: possible involvement of GABAA receptors and 5-HT1A receptors. Biomol Ther 2012, 20:413-417.
16. Hoyer D., Martin G. 5-HT receptor classification and nomenclature: towards a harmonization with the human genome. Neuropharmacology 1997, 36:419-428.
17. Hua H., Feng L., Zhang X.P., Zhang L.F., Jin J. Anti-angiogenic activity of Julibroside J8, a natural product isolated from Albizzia julibrissin. Phytomedicine 2009, 16:703-711.
18. Hui K.M., Huen M.S.Y., Wang H.Y., Zheng H., Sigel E., Baur R., et al. Anxiolytic effect of wogonin, a benzodiazepine receptor ligand isolated from Scutellaria baicalensis Georgi. Biochem Pharmacol 2002, 64:1415-1424.
19. Jung M.J., Kang S.S., Jung Y.J., Choi J.S. Phenolic glycosides from the stem bark of Albizzia julibrissin. Chem Pharm Bull 2004, 52:1501-1503.
20. Jung J.W., Cho J.H., Ahn N.Y., Oh H.R., Kim S.Y., Jang C.G., et al. Effect of chronic Albizzia julibrissin treatment on 5-hydroxytryptamine1A receptors in rat brain. Pharmacol Biochem Behav 2005, 81:205-210.
21. Kang T.H., Jeong S.J., Kim N.Y., Higuchi R., Kim Y.C. Sedative activity of two flavonol glycosides isolated from the flowers of Albizzia julibrissin Durazz. J Ethnopharmacol 2000, 71:321-323.
22. Karim N., Curmi J., Gavande N., Johnston G.A., Hanrahan J.R., Tierney M.L., et al. 2'-Methoxy-6-methylflavone: a novel anxiolytic and sedative with subtype selective activating and modulating actions at GABA A receptors. Br J Pharmacol 2012, 165:880-896.
23. Kataoka Y., Shibata K., Miyazaki A., Inoue Y., Tominaga K., Koizumi S., et al. Involvement of the dorsal hippocampus in mediation of the antianxiety action of tandospirone, a 5-hydroxytryptamine(1A) agonistic anxiolytic. Neuropharmacology 1991, 30:475-480.
24. Kessler R.C., Angermeyer M., Anthony J.C., De Graaf R., Demyttenaere K., Gasquet Iea Lifetime prevalence and age-of-onset distributions of mental disorders in the World Health Organization's World Mental Health Survey initiative. World Psychiatry 2007, 6:168-176.
25. Kim W.K., Jung J.W., Ahn N.Y., Oh H.R., Lee B.K., Oh J.K., et al. Anxiolytic-like effects of extracts from Albizzia julibrissin bark in the elevated plus-maze in rats. Life Sci 2004, 75:2787-2795.
26. Kinjo J., Araki K., Fukui K., Higuchi H., Ikeda T., Nohara T., et al. Six new tritrepenoidal glycosides including two new sapogenols from Albizziae Cortex. V. Chem Pharm Bull 1992, 40:3269-3273.
27. Kostowski W., Plaznik A., Stefanski R. Intra-hippocampal buspirone in animal models of anxiety. Eur J Pharmacol 1989, 168:393-396.
28. Lesch K.P. Modulation of receptor-G protein complex function by psychotropic drugs and glucocorticoids: implications for anxiety disorder and depression. Eur Neuropsychopharmacol 1991, 1:340-341.
29. Liang H., Tong W.Y., Zhao Y.Y., Cui J.R., Tu G.Z. An antitumor compound Julibroside J28 from Albizzia julibrissin. Bioorg Med Chem Lett 2005, 15:4493-4495.
30. Liao J.F., Hung W.Y., Chen C.F. Anxiolytic-like effects of baicalein and baicalin in the Vogel conflict test in mice. Eur J Pharmacol 2003, 464:141-146.
31. Lister R.G. The use of a plus-maze to measure anxiety in the mouse. Psychopharmacology 1987, 92:180-185.
32. Mohler H., Benke D., Benson J., Luscher B., Fritschy J.M. GABAA-receptor subtypes in vivo: cellular localization, pharmacology and regulation. Adv Biochem Psychopharmacol 1995, 48:41-56.
33. Nemeroff C.B. Anxiolytics: past, present, and future agents. J Clin Psychiatry 2003, 64:3-6.
34. Ninan P.T. The functional anatomy, neurochemistry, and pharmacology of anxiety. J Clin Psychiatry 1999, 60:12-17.
35. Nutt D.J., Malizia A.L. New insights into the role of the GABAA-benzodiazepine receptor in psychiatric disorder. Br J Psychiatry 2001, 179:390-396.
36. Oh S., Jang C.G., Ma T., Ho I.K. Activation of protein kinase C by phorbol dibutyrate modulates GABA(A) receptor binding in rat brain slices. Brain Res 1999, 850:158-165.
37. Okazawa H., Yamane F., Blier P., Diksic M. Effects of acute and chronic administration of the serotonin(1A) agonist buspirone on serotonin synthesis in the rat brain. J Neurochem 1999, 72:2022-2031.
38. Olsen R.W., Sieghart W. International Union of Pharmacology. LXX. Subtypes of γ-aminobutyric acidA receptors: classification on the basis of subunit composition, pharmacology, and function. Update. Pharmacol Rev 2008, 60:243-260.
39. Overstreet D.H., Commissaris R.C., De la Garza R., File S.E., Knapp D.J., Seiden L.S. Involvement of 5-HT1A receptors in animal tests of anxiety and depression: evidence from genetic models. Stress 2003, 6:101-110.
40. Rabow L.E., Russek S.J., Farb D.H. From ion currents to genomic analysis: recent advances in GABA(A) receptor research. Synapse 1995, 21:189-274.
41. Ren L., Wang F., Xu Z., Chan W.M., Zhao C., Xue H. GABA A receptor subtype selectivity underlying anxiolytic effect of 6-hydroxyflavone. Biochem Pharmacol 2010, 79:1337-1344.
42. Rudolph U., Crestani F., Benke D., Brunig I., Benson J.A., Fritschy J.M., et al. Benzodiazepine actions mediated by specific γ-aminobutyric acid(A) receptor subtypes. Nature 1999, 401:796-800.
43. Schreiber R., De Vry J. 5-HT(1A) receptor ligands in animal models of anxiety, impulsivity and depression: multiple mechanisms. Prog Neuropsychopharmacol Biol Psychiatry 1993, 17:87-104.
44. Singh Y.N., Singh N.N. Therapeutic potential of kava in the treatment of anxiety disorders. CNS Drugs 2002, 16:731-743.
45. Sundstrom I., Ashbrook D., Backstrom T. Reduced benzodiazepine sensitivity in patients with premenstrual syndrome: a pilot study. Psychoneuroendocrinology 1997, 22:25-38.
46. 3H]muscimol binding in the rat hippocampus: a quantitative autoradiographic study. Neuroscience 1994, 59:817-826.
47. Uchiyama H., Yamaguchi T., Toda A., Hiranita T., Watanabe S., Eyanagi R. Involvement of the GABA/benzodiazepine receptor in the anxiolytic-like effect of nociceptin/orphanin FQ. Eur J Pharmacol 2008, 590:185-189.
48. Uhlenhuth E.H., Balter M.B., Ban T.A., Yang K. International study of expert judgment on therapeutic use of benzodiazepines and other psychotherapeutic medications: VI. Trends in recommendations for the pharmacotherapy of anxiety disorders, 1992-1997. Depress Anxiety 1999, 9:107-116.
49. Viola H., Wasowski C., Levi De Stein M., Wolfman C., Silveira R., Dajas F., et al. Apigenin, a component of Matricaria recutita flowers, is a central benzodiazepine receptors-ligand with anxiolytic effects. Planta Med 1995, 61:213-216.
50. Wang F., Huen M.S.Y., Tsang S.Y., Xue H. Neuroactive flavonoids interacting with GABAA receptor complex. Curr Drug Targets CNS Neurol Disord 2005, 4:575-585.
51. Wieronska J.M., Stachowicz K., Palucha-Poniewiera A., Acher F., Branski P., Pilc A. Metabotropic glutamate receptor 4 novel agonist LSP1-2111 with anxiolytic, but not antidepressant-like activity, mediated by serotonergic and GABAergic systems. Neuropharmacology 2010, 59:627-634.
52. Xu Z., Wang F., Tsang S.Y., Ho K.H., Zheng H., Yuen C.T., et al. Anxiolytic-like effect of baicalin and its additivity with other anxiolytics. Planta Med 2006, 72:189-192.
53. Yoo J.I.H., Lee S.Y., Loh H.H., Ho I.K., Jang C.G. Altered emotional behaviors and the expression of 5-HT1A and M1 muscarinic receptors in μ-opioid receptor knockout mice. Synapse 2004, 54:72-82.
54. Yoon B., Choi J., Jung J., Shin J., Hyeon S., Cheong J. Anxiolytic-like effects of phenylpropanoids using the elevated plus-maze in mice. Yakhak Hoeji 2005, 49:437-442.
55. Yu H.S., Lee S.Y., Jang C.G. Involvement of 5-HT1A and GABAA receptors in the anxiolytic-like effects of Cinnamomum cassia in mice. Pharmacol Biochem Behav 2007, 87:164-170.
56. Zhu Y. Chinese materia medica chemistry, pharmacology and applications 1998, 519-520. Harwood Academic Publishers, Netherlands.